GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Cancer) congress.
The 11th ISMRC symposium will take place from 3rd to 5th of May in Montpellier, France and is focused on “Minimal Residual Cancer in patients with solid tumors”. This congress brings together researchers from academia and industry sharing information about liquid biopsy. The program will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes with an emphasis on clinical studies and the biology of metastasis.
GILUPI will use this opportunity to present data from clinical settings with focus on therapy-relevant targets in lung and prostate cancer detected on CTCs by using the in vivo GILUPI CellCollector® technology. The poster presentation (P-54) will take place on Thursday 3rd of May at 2.30 pm - 3.20 pm. You are invited to meet the CEO of GILUPI Dr. Christian Jurinke.
The 11th ISMRC symposium will take place from 3rd to 5th of May in Montpellier, France and is focused on “Minimal Residual Cancer in patients with solid tumors”. This congress brings together researchers from academia and industry sharing information about liquid biopsy. The program will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes with an emphasis on clinical studies and the biology of metastasis.
GILUPI will use this opportunity to present data from clinical settings with focus on therapy-relevant targets in lung and prostate cancer detected on CTCs by using the in vivo GILUPI CellCollector® technology. The poster presentation (P-54) will take place on Thursday 3rd of May at 2.30 pm - 3.20 pm. You are invited to meet the CEO of GILUPI Dr. Christian Jurinke.
